In the context of the CRC TME, TILs represent a heterogeneous mixture of adaptive immune cells, comprising mainly anti-tumour T cells (CD4+ and CD8+ subsets) and suppressive CD4+ T cells (Treg) [28]. The gene discussed is CD4; the disease is colorectal carcinoma.